Following the announcement of Sun Pharmaceuticals Industries (Sun) acquiring Ranbaxy, we upgrade Sun Pharma to ?buy? (earlier ?neutral?) with a revised price objective of R680 (24x FY16e), a 20% ...
Sun Pharma, including its subsidiaries and/or associate companies), announced that Sun Pharma has received final approval from USFDA for its abbreviated new Drug application (ANDA) for generic version ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈